Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging
- PMID: 39012502
- DOI: 10.1007/s00259-024-06843-2
Quinazoline-2,4(1 H,3 H)-dione Scaffold for development of a novel PARP-targeting PET probe for tumor imaging
Abstract
Purpose: Overexpression of Poly (ADP-ribose) polymerase (PARP) is associated with many diseases such as oncological diseases. Several PARP-targeting radiotracers have been developed to detect tumor in recent years. Two 18F labelled probes based on Olaparib and Rucaparib molecular scaffolds have been evaluated in clinical trials, but their slow hepatic clearance hinders their tumor imaging performance. Although a number of positron emission tomography (PET) probes with lower liver uptake have been designed, the tumor to background ratios remains to be low. Therefore, we designed a probe with low lipid-water partition coefficient to solve this problem.
Methods: A pyridine-containing quinazoline-2,4(1 H,3 H)-dione PARP-targeting group was rationally designed and used to conjugate with the chelator 2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid (DOTA) to prepare the lead compound named as SMIC-2001 for radiolabeling. In vitro experiments, the lipid-water partition coefficient, stability, binding affinity, and cellular uptake of [68Ga]Ga-SMIC-2001 were determined. In vivo experiments, the U87MG xenograft models were used to evaluate its tumor imaging properties.
Results: [68Ga]Ga-SMIC-2001 showed a low Log D7.4 (-3.82 ± 0.06) and high affinity for PARP-1 (48.13 nM). In vivo study revealed that it exhibited a high tumor-to-background contrast in the U87MG xenograft models and mainly renal clearance. And the ratios of tumor to main organs were high except for the kidney (e.g. tumor to liver ratio reached 2.20 ± 0.51) at 60 min p.i.
Conclusion: In summary, pyridine-containing quinazoline-2,4(1 H,3 H)-dione is a novel PARP-targeting molecular scaffold for imaging probe development, and [68Ga]Ga-SMIC-2001 is a highly promising PET probe capable of imaging tumors with PARP overexpression.
Keywords: Oncology; PARP; PET/CT; Quinazoline-2,4(1H,3H)-dione.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
PET imaging of PARP expression using 68Ga-labelled inhibitors.Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2606-2620. doi: 10.1007/s00259-023-06249-6. Epub 2023 May 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 37145164 Free PMC article.
-
Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma.Mol Pharm. 2023 Aug 7;20(8):4120-4128. doi: 10.1021/acs.molpharmaceut.3c00248. Epub 2023 Jul 24. Mol Pharm. 2023. PMID: 37487027
-
Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.Bioorg Med Chem. 2015 Feb 15;23(4):681-93. doi: 10.1016/j.bmc.2014.12.071. Epub 2015 Jan 8. Bioorg Med Chem. 2015. PMID: 25614115
-
Design, Synthesis, and Evaluation of [18F]BIBD-300 as a Positron Emission Tomography Tracer for Poly(ADP-Ribose) Polymerase-1.Mol Pharm. 2024 May 6;21(5):2606-2621. doi: 10.1021/acs.molpharmaceut.4c00262. Epub 2024 Apr 12. Mol Pharm. 2024. PMID: 38606716
-
Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.Bioorg Med Chem. 2014 Mar 1;22(5):1700-7. doi: 10.1016/j.bmc.2014.01.019. Epub 2014 Jan 24. Bioorg Med Chem. 2014. PMID: 24503274 Free PMC article.
Cited by
-
Non-invasive diagnosis of liver fibrosis via MRI using targeted gadolinium-based nanoparticles.Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):48-61. doi: 10.1007/s00259-024-06894-5. Epub 2024 Sep 5. Eur J Nucl Med Mol Imaging. 2024. PMID: 39231880
-
Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging.EJNMMI Radiopharm Chem. 2025 Jul 3;10(1):37. doi: 10.1186/s41181-025-00364-5. EJNMMI Radiopharm Chem. 2025. PMID: 40608261 Free PMC article. Review.
-
Development and evaluation of a 99mTc-labeled olaparib analog for PARP imaging.EJNMMI Radiopharm Chem. 2025 Jul 22;10(1):46. doi: 10.1186/s41181-025-00373-4. EJNMMI Radiopharm Chem. 2025. PMID: 40694243 Free PMC article.
References
-
- Schwarz SD, Xu J, Gunasekera K, Schürmann D, Vågbø CB, Ferrari E, et al. Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation. Nat Commun. 2024;15:184. https://doi.org/10.1038/s41467-023-44209-8 . - DOI - PubMed - PMC
-
- Zandarashvili L, Langelier MF, Velagapudi UK, Hancock MA, Steffen JD, Billur R, et al. Structural basis for allosteric PARP-1 retention on DNA breaks. Science. 2020;368:eaax6367. https://doi.org/10.1126/science.aax6367 . - DOI - PubMed - PMC
-
- Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discovery. 2020;19:711–36. https://doi.org/10.1038/s41573-020-0076-6 . - DOI - PubMed
-
- Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer. Nat Cancer. 2022;3:927–31. https://doi.org/10.1038/s43018-022-00400-2 . - DOI - PubMed - PMC
-
- Gruber JJ, Afghahi A, Timms K, DeWees A, Gross W, Aushev VN, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat Cancer. 2022;3:1181–91. https://doi.org/10.1038/s43018-022-00439-1 . - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
- U2267221/National Natural Science Foundation of China
- TM202301H003/Shanghai Municipal Science and Technology Major Project
- SIMM0120231004/State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- 23ZDFA014/Gansu Science and Technology Major Project
- SYS202205/the Shandong Laboratory Program
LinkOut - more resources
Full Text Sources
Miscellaneous